| Literature DB >> 31289363 |
Xiuhui Chen1,2, Lingegowda S Mangala3,4, Linda Mooberry5, Emine Bayraktar1,6, Santosh K Dasari1, Shaolin Ma1, Cristina Ivan6,7, Karem A Court1, Cristian Rodriguez-Aguayo6,7, Recep Bayraktar7, Sangram Raut5, Nirupama Sabnis5, Xianchao Kong2, Xianbin Yang8, Gabriel Lopez-Berestein6,7, Andras G Lacko5,9, Anil K Sood10,11,12.
Abstract
Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein-nanoparticles (rHDL-NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31289363 PMCID： PMC7293105 DOI： 10.1038/s41388-019-0862-y
Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867